Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
HEDoctoral network2022–2027

STOP SPREAD BAD BUGS · novel antimicrobial approaches to combat multidrug resistance in bacteria

Horizon Europe — Marie Skłodowska-Curie Actions

Duration
2022-09-01 → 2027-08-31
EU contribution
€3,972,294
Participants
28
Scheme
HORIZON-TMA-MSCA-DN-ID

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

STOP SPREAD BAD BUGS: novel antimicrobial approaches to combat multidrug resistance in bacteria

STOP SPREAD BAD BUGS (SSBB) is a new multi-disciplinary research and training consortium built to combat the alarming problem of global antimicrobial resistance. Multi-drug resistance in bacteria is becoming increasingly common thus urgently calling for alternative approaches to develop and implement novel antibiotics. A state-of-the-art research and training pipeline shall be developed and implemented by the SSBB consortium, a unique network of academic and non-academic world-renowned experts in the field of drug development, infectiology, immunology and pharmacology. The SSBB research and training pipeline will train a new generation of 15 Doctoral Candidates (DCs) providing them with complementary expertise in the development and testing of novel approaches to antimicrobial therapy in humans. The SSBB consortium establishes knowledge and expertise for the discovery of new drug candidates. The SSBB project aims to: 1. Train a new generation of researchers with complementary expertise in the development and testing of novel approaches to antimicrobial therapy. 2. Develop new compounds with antimicrobial activity. 3. Generate state-of-the-art tools and analyze target and off-target effects of the new antimicrobials. 4. Test antibiotic efficacy of the new antimicrobials in respiratory and intestinal tract infection models as well as in models for infections of surgically implantable devices.

Data: CORDIS, © European Union

Project objective

STOP SPREAD BAD BUGS is a new multi-disciplinary research/training consortium built to combat the alarming problem of global antimicrobial resistance. Multi-drug resistance (MDR) in bacteria is becoming increasingly common thus urgently calling for alternative approaches to develop and implement novel antibiotics. We envision a definitive solution that will require a paradigm shift. Its foundation shall be the training of a new generation of future 15 Early Stage Researchers (ESRs) by world-renowned experts in the field of drug development, infectiology, immunology and pharmacology. A unique state-of the-art teaching/training pipeline shall be developed across 7 academic and 5 SME partners with complementary expertise in the development and testing of novel approaches to antimicrobial therapy in humans. We shall establish knowledge and expertise on carbohydrate and protein chemistry for the discovery of new drug candidates, while characterizing the underlying mechanism of existing compounds for treatment of microbial infections. Computational modelling shall optimize the interactions of the novel entities with selected pathogens. A range of infection models allows partners to simultaneously determine compound efficacy in pre-clinical settings and investigate the potential effects of the novel antimicrobials on host tissues. State-of-the-art imaging tools will be applied to track the bacteria and novel compounds in these test systems. Uniquely, the pipeline will also determine the pharmacokinetics, and the effects of compounds on host microbiota and host immunity. Understanding the mechanisms of action of the novel antimicrobials shall provide insights into new antimicrobial mechanisms, which may be further exploited in spin-off projects. This approach means that the STOP SPREAD BAD BUGS consortium will deliver uniquely trained, multi- and interdisciplinary ESRs that will take the continuing fight against global MDR safely into the future.

Original text from CORDIS.

Participants

  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamCoordinatorNetherlands
  • ANITOM · AartselaarBelgium
  • AQUILON PHARMACEUTICALS SA · VISEBelgium
  • ASSOCIAZIONE TOURISM · NEMIItaly
  • CHEMPRECISE CONSULTORIA BIOTECNOLOGIA PRODUTOS FARMACEUTICOS E IMOBILIARIO LDA · TORRES VEDRASPortugal
  • DES SOLUTIO - SOLUCOES E CONSULTORIA CIENTIFICA LDA · Charneca De CaparicaPortugal
  • FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaItaly
  • Faculdade de Farmácia da Universidade de Lisboa · LisboaPortugal
  • HYLOMORPH AG · ZurichSwitzerland
  • INBIOSE · ZWIJNAARDEBelgium
  • INNOSO BV · 's-Gravenhage (Den Haag)City levelNetherlands
  • INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTARIES · CALDES DE MONTBUI BARCELONASpain
  • MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENGermany
  • MEDIZINISCHE UNIVERSITAET WIEN · WienAustria
  • MEDRES-MEDICAL RESEARCH GMBH · KolnGermany
  • NUTRITION SCIENCES · DrongenBelgium
  • PHILIPPS UNIVERSITAET MARBURG · MarburgGermany
  • PROGREDUM GMBH · KaiserslauternGermany
  • SETLANCE SRL · SienaItaly
  • THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
  • TISSUEGNOSTICS GMBH · WienAustria
  • UNIVERSITA DEGLI STUDI DI SIENA · SienaItaly
  • UNIVERSITAT AUTONOMA DE BARCELONA · Cerdanyola Del VallesSpain
  • UNIVERSITE DE LIEGE · LIEGEBelgium
  • UNIVERSITEIT GENT · GentBelgium
  • UNIVERSITEIT UTRECHT · UtrechtNetherlands
  • UNIVERSITETET I STAVANGER · StavangerNorway
  • UNIVERSITY OF GLASGOW · GlasgowUnited Kingdom

Links

Data: CORDIS, © European Union